title: Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
authors.affiliation: Cardiavant, Cardiologic Medical Center, Las Palmas de Gran Canaria, Spain - fwanguemert@mac.com.
authors.forename: F
authors.initials: F
authors.lastname: Wangüemert-Pérez
authors.forename: P M
authors.initials: PM
authors.lastname: Ruiz-Hernández
authors.forename: O
authors.initials: O
authors.lastname: Campuzano
authors.forename: E
authors.initials: E
authors.lastname: Caballero-Dorta
authors.forename: C
authors.initials: C
authors.lastname: Bosch
authors.forename: J
authors.initials: J
authors.lastname: Brugada
authors.forename: R
authors.initials: R
authors.lastname: Brugada
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004562:Electrocardiography; D005424:Flecainide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics*; D017180:Tachycardia, Ventricular / Q000188:drug therapy* / Q000235:genetics; D000098850:Polymorphic Catecholaminergic Ventricular Tachycardia
chemical_list: D000889:Anti-Arrhythmia Agents; D019837:Ryanodine Receptor Calcium Release Channel; D005424:Flecainide